Objective: To assess the efficacy of single intravitreal injection of ranibizumab with laser photocoagulation for the treatment of macular edema secondary to branch retinal vein occlusion (BRVO). Methods: In this retrospective study, 52 patients (52 eyes) during June 2014 to December 2016 at Taizhou Municipal Hospital with macular edema secondary to BRVO were diagnosed by fundus fluorescence angiography. The patients were divided into two groups, one receiving laser photocoagulation alone and the other receiving a single intravitreal injection of ranibizumab. The injection group was further divided into two groups,one receiving the injection before laser therapy and one receiving afterwards. The best corrected visual acuity (BCVA) and central macular thickness (CMT) were recorded before the therapy and at one and six
months afterwards. Repeated measurement analysis of variance, one-way analysis of variance, and paired t-tests were used to analyze the data. Results: Before the therapy, and at one and six months after therapy,the total difference of BCVA among the three groups was statistically significant (F=18.28, P=0.011).Objective: To assess the efficacy of single intravitreal injection of ranibizumab with laser photocoagulation for the treatment of macular edema secondary to branch retinal vein occlusion (BRVO). Methods: In this retrospective study, 52 patients (52 eyes) during June 2014 to December 2016 at Taizhou Municipal Hospital with macular edema secondary to BRVO were diagnosed by fundus fluorescence angiography. The patients were divided into two groups, one receiving laser photocoagulation alone and the other receiving a single intravitreal injection of ranibizumab. The injection group was further divided into two groups,one receiving the injection before laser therapy and one receiving afterwards. The best corrected visual acuity (BCVA) and central macular thickness (CMT) were recorded before the therapy and at one and six months afterwards. Repeated measurement analysis of variance, one-way analysis of variance, and paired t-tests were used to analyze the data. Results: Before the therapy, and at one and six months after therapy,the total difference of BCVA among the three groups was statistically significant (F=18.28, P=0.011).
徐志伟,伍海建,金玲艳,颜管根. 单次玻璃体腔注射雷珠单抗联合激光治疗视网膜分支静脉阻塞继发黄斑水肿[J]. 中华眼视光学与视觉科学杂志, 2018, 20(3): 168-173.
Zhiwei Xu,Haijian Wu,Lingyan Jin,Guangen Yan. Single Intravitreal Injection of Ranibizumab with Laser Photocoagulation for Macular Edema Following Branch Retinal Vein Occlusion. Chinese Journal of Optometry Ophthalmology and Visual science, 2018, 20(3): 168-173. DOI: 10.3760/cma.j.issn.1674-845X.2018.03.008
Klein R, Moss SE, Meuer SM, et al. The 15-year cumulative incidence of retinal vein occlusion: The Beaver Dam Eye Study. Arch Ophthalmol, 2008, 126(4): 513-518. DOI: 10.1001/
archopht.126.4.513.
[2]
Rogers SL, McIntosh RL, Lim L, et al. Natural history of branch retinal vein occlusion: an evidence-based systematic review.Ophthalmology, 2010, 117(6): 1094-1101. DOI: 10.1016/
archopht.126.4.513.
[2]
Rogers SL, McIntosh RL, Lim L, et al. Natural history of branch retinal vein occlusion: an evidence-based systematic review.Ophthalmology, 2010, 117(6): 1094-1101. DOI: 10.1016/
j.ophtha.2010.01.058.
j.ophtha.2010.01.058.
[3]
Argon laser photocoagulation for macular edema in branch vein occlusion. The Branch Vein Occlusion Study Group. Am J Ophthalmol, 1984, 98(3): 271-282.
Pielen A, Mirshahi A, Feltgen N, et al. Ranibizumab for Branch Retinal Vein Occlusion Associated Macular Edema Study (RABAMES): six-month results of a prospective randomized
Regnier SA, Larsen M, Bezlyak V, et al. Comparative efficacy and safety of approved treatments for macular oedema secondary to branch retinal vein occlusion: a network metaanalysis.BMJ Open, 2015, 5(6): e007527. DOI: 10.1136/bmjopen-2014-007527.
[7]
Pielen A, Mirshahi A, Feltgen N, et al. Ranibizumab for Branch Retinal Vein Occlusion Associated Macular Edema Study (RABAMES): six-month results of a prospective randomized
Regnier SA, Larsen M, Bezlyak V, et al. Comparative efficacy and safety of approved treatments for macular oedema secondary to branch retinal vein occlusion: a network metaanalysis.BMJ Open, 2015, 5(6): e007527. DOI: 10.1136/bmjopen-2014-007527.
[10]
Tadayoni R, Waldstein SM, Boscia F, et al. Individualized Stabilization Criteria-Driven Ranibizumab versus Laser in Branch Retinal Vein Occlusion: Six-Month Results of
Tan MH, McAllister IL, Gillies ME, et al. Randomized controlled trial of intravitreal ranibizumab versus standard grid laser for macular edema following branch retinal vein occlusion.
Am J Ophthalmol, 2014, 157(1): 237-247.e1. DOI: 10.1016/j.ajo.2013.08.013.
[11]
Tan MH, McAllister IL, Gillies ME, et al. Randomized controlled trial of intravitreal ranibizumab versus standard grid laser for macular edema following branch retinal vein occlusion.
Am J Ophthalmol, 2014, 157(1): 237-247.e1. DOI: 10.1016/j.ajo.2013.08.013.
[12]
Campochiaro PA, Heier JS, Feiner L, et al. Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase Ⅲ study.
Brown DM, Campochiaro PA, Bhisitkul RB, et al. Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase Ⅲ study.Ophthalmology, 2011, 118(8): 1594-1602. DOI: 10.1016/j.ophtha.2011.02.022.
[14]
Campochiaro PA, Sophie R, Pearlman J, et al. Long-term outcomes in patients with retinal vein occlusion treated with ranibizumab: the RETAIN study. Ophthalmology, 2014, 121(1):209-219. DOI: 10.1016/j.ophtha.2013.08.038.
[15]
Heier JS, Campochiaro PA, Yau L, et al. Ranibizumab for macular edema due to retinal vein occlusions: long-term followup in the HORIZON trial. Ophthalmology, 2012, 119(4): 802-809. DOI: 10.1016/j.ophtha.2011.12.005.
[16]
C a m p o c h i a r o PA , H a f i z G , M i r TA , e t a l . S c a t t e r photocoagulation does not reduce macular edema or treatment burden in patients with retinal vein occlusion: The RELATE Trial. Ophthalmology, 2015, 122(7): 1426-1437. DOI: 10.1016/j.ophtha.2015.04.006.
[12]
Campochiaro PA, Heier JS, Feiner L, et al. Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase Ⅲ study.
Brown DM, Campochiaro PA, Bhisitkul RB, et al. Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase Ⅲ study.Ophthalmology, 2011, 118(8): 1594-1602. DOI: 10.1016/j.ophtha.2011.02.022.
[14]
Campochiaro PA, Sophie R, Pearlman J, et al. Long-term outcomes in patients with retinal vein occlusion treated with ranibizumab: the RETAIN study. Ophthalmology, 2014, 121(1):209-219. DOI: 10.1016/j.ophtha.2013.08.038.
[15]
Heier JS, Campochiaro PA, Yau L, et al. Ranibizumab for macular edema due to retinal vein occlusions: long-term followup in the HORIZON trial. Ophthalmology, 2012, 119(4): 802-809. DOI: 10.1016/j.ophtha.2011.12.005.
[16]
C a m p o c h i a r o PA , H a f i z G , M i r TA , e t a l . S c a t t e r photocoagulation does not reduce macular edema or treatment burden in patients with retinal vein occlusion: The RELATE Trial. Ophthalmology, 2015, 122(7): 1426-1437. DOI: 10.1016/j.ophtha.2015.04.006.
浙公网安备 33030202001892号